Special Issue

Thalassemia Syndromes as a Benign Cancer of Hematopoietic Stem Cells

Message from the Guest Editors

The thalassemia syndrome is a genetic disorder, due mainly to more than 250 beta globin gene point mutations, affecting the proliferation of the hematopoietic stem cell leading to ineffective erythropoiesis with lack of differentiation of the erythroid clone and severe anemia. The thalassemia syndrome is not commonly perceived as a proliferative congenital hematopoietic stem cell disorder of the erythroid clone but simply as a congenital anemia. However, technical challenges, accessibility and sustainability of such strategies caused over a 40 year delay before some started becoming available at the patient bedside. This Special Issue would like to address the background and the implication, in the next future, for considering thalassemia syndromes as a proliferative congenital hematopoietic stem cell disorder of the erythroid clone. ***The first 10 papers published in this Special Issue will be free of charge.**

Guest Editors

Prof. Dr. Aurelio Maggio
Campus of Haematology Franco e Piera Cutino, Foundation Franco and Piera Cutino, A.O.O.R. "Villa Sofia-Cervello", 90146 Palermo, Italy
Prof. Dr. Andrea Piccin
Northern Ireland Blood Transfusion Service, NIBTS, Belfast, UK

Deadline for manuscript submissions

closed (28 February 2023)

Thalassemia Reports

an Open Access Journal by MDPI

Impact Factor 1.2

mdpi.com/si/127894

Thalassemia Reports
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
thalassrep@mdpi.com

mdpi.com/journal/thalassrep

Thalassemia Reports

an Open Access Journal by MDPI

Impact Factor 1.2

mdpi.com/journal/thalassrep

About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Aurelio Maggio
Foundation Franco and Piera Cutino, Villa Sofia-Cervello Hospital, Palermo, Italy

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within ESCI (Web of Science), Embase, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 42.6 days after submission; acceptance to publication is undertaken in 6.9 days (median values for papers published in this journal in the second half of 2025).